Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-03-15, Stock:PFE, The news for the past five days is as follows:
2019-03-08: NEWS1: After Hours Most Active for Mar 8, 2019 :  LLY, PFE, ORCL, MRO, JD, QQQ, EBAY, T, GE, URBN, MSFT, IEF.NEWS2: After Hours Most Active for Mar 8, 2019 :  LLY, PFE, ORCL, MRO, JD, QQQ, EBAY, T, GE, URBN, MSFT, IEF.NEWS3: Pharma Stock Roundup: FDA OK's J&J Antidepressant, CHMP Recommends Several Drugs.NEWS4: Pharma Stock Roundup: FDA OK's J&J Antidepressant, CHMP Recommends Several Drugs.NEWS5: Pharma Stock Roundup: FDA OK's J&J Antidepressant, CHMP Recommends Several Drugs.NEWS6: Exchange Traded Funds: How To Find The Best ETFs.NEWS7: Health Care Sector Update for 03/08/2019: SEEL, ACET, ARDX, JNJ, PFE, ABT, MRK, AMGN.NEWS8: Health Care Sector Update for 03/08/2019: SEEL, ACET, ARDX, JNJ, PFE, ABT, MRK, AMGN.
2019-03-11: NEWS1: U.S. FDA Approves Pfizer’s Oncology Biosimilar TRAZIMERA™ (trastuzumab-qyyp), a Biosimilar to Herceptin®1.NEWS2: Stocks Spike on M&A and Retail Sales.NEWS3: FDA approves Pfizer's biosimilar to Roche's Herceptin.NEWS4: FDA approves Pfizer's biosimilar to Roche's Herceptin.NEWS5: Conatus' (CNAT) Q4 Earnings Top Estimates, Emricasan in Focus.NEWS6: Conatus' (CNAT) Q4 Earnings Top Estimates, Emricasan in Focus.NEWS7: The Zacks Analyst Blog Highlights: J&J, Lilly, Pfizer, AstraZeneca and Merck's.NEWS8: The Zacks Analyst Blog Highlights: J&J, Lilly, Pfizer, AstraZeneca and Merck's.NEWS9: Conatus' (CNAT) Q4 Earnings Top Estimates, Emricasan in Focus.NEWS10: The Zacks Analyst Blog Highlights: J&J, Lilly, Pfizer, AstraZeneca and Merck's.NEWS11: Health Care Sector Update for 03/11/2019: AXGT, LCI, HRC, JNJ, PFE, MRK, ABT, AMGN.NEWS12: Health Care Sector Update for 03/11/2019: AXGT, LCI, HRC, JNJ, PFE, MRK, ABT, AMGN.
2019-03-12: NEWS1: BioNTech hires banks for IPO worth up to $800 million -sources.NEWS2: BioNtech hires banks for IPO worth up to $800 million - sources.NEWS3: Biontech stock offering could be worth as much as $800 million-sources.NEWS4: Option trading opportunities in Pfizer & Sirius XM.NEWS5: Pfizer's Herceptin Biosimilar Trazimera Gets FDA Approval.NEWS6: Pfizer's Herceptin Biosimilar Trazimera Gets FDA Approval.NEWS7: Pfizer's (PFE) Kidney Cancer Drug Combo Gets EMA's Validation.NEWS8: Pfizer's (PFE) Kidney Cancer Drug Combo Gets EMA's Validation.NEWS9: Pfizer's Herceptin Biosimilar Trazimera Gets FDA Approval.NEWS10: See what the IHS Markit Score report has to say about Pfizer Inc..NEWS11: Pfizer's (PFE) Kidney Cancer Drug Combo Gets EMA's Validation.NEWS12: Health Care Sector Update for 03/12/2019: ZFGN, AKBA, HEXO, JNJ, PFE, ABT, MRK, AMGN.NEWS13: Health Care Sector Update for 03/12/2019: ZFGN, AKBA, HEXO, JNJ, PFE, ABT, MRK, AMGN.NEWS14: Why Novartis is a Top 10 SAFE International Dividend Stock (NVS).NEWS15: Why Novartis is a Top 10 SAFE International Dividend Stock (NVS).
2019-03-13: NEWS1: Pfizer (PFE) Gains But Lags Market: What You Should Know.NEWS2: After Hours Most Active for Mar 13, 2019 :  MSFT, LLY, F, CMCSA, PFE, FOX, CTL, HPQ, PCG, AMD, AAPL, ENDP.NEWS3: After Hours Most Active for Mar 13, 2019 :  MSFT, LLY, F, CMCSA, PFE, FOX, CTL, HPQ, PCG, AMD, AAPL, ENDP.NEWS4: Aerie (AERI) Receives FDA Nod for Rocklatan to Treat Glaucoma.NEWS5: Aerie (AERI) Receives FDA Nod for Rocklatan to Treat Glaucoma.NEWS6: Lilly's Cyramza Successful in Phase III First-Line NSCLC Study.NEWS7: Lilly's Cyramza Successful in Phase III First-Line NSCLC Study.NEWS8: Theravance (TBPH) Starts Dosing in Ulcerative Colitis Study.NEWS9: Lilly's Cyramza Successful in Phase III First-Line NSCLC Study.NEWS10: Dow Analyst Moves: PFE.NEWS11: Dow Analyst Moves: PFE.NEWS12: Aerie (AERI) Receives FDA Nod for Rocklatan to Treat Glaucoma.NEWS13: Health Care Sector Update for 03/13/2019: NVCN, CASI, LXRX, JNJ, PFE, ABT, MRK, AMGN.NEWS14: Health Care Sector Update for 03/13/2019: NVCN, CASI, LXRX, JNJ, PFE, ABT, MRK, AMGN.NEWS15: Merck & Company, Inc. (MRK) Ex-Dividend Date Scheduled for March 14, 2019.NEWS16: Merck & Company, Inc. (MRK) Ex-Dividend Date Scheduled for March 14, 2019.NEWS17: FDA medical adviser: 'Congress is owned by pharma'.
2019-03-14: NEWS1: S&P, Nasdaq Snap Win Streaks in Down Day for Stocks.NEWS2: S&P, Nasdaq Snap Win Streaks in Down Day for Stocks.NEWS3: After Hours Most Active for Mar 14, 2019 :  GCP, LLY, HPQ, F, PFE, ACB.NEWS4: After Hours Most Active for Mar 14, 2019 :  GCP, LLY, HPQ, F, PFE, ACB.NEWS5: Market Close Report: NASDAQ Composite index closes at 7,630.91 down -12.50 points.NEWS6: Market Close Report: NASDAQ Composite index closes at 7,630.91 down -12.50 points.NEWS7: Markets Right Now: Stocks end a wobbly day mostly lower.NEWS8: What's the play on Wynn? Plus the trades on Citigroup & Pfizer in #AskHalftime.NEWS9: Health Care Sector Update for 03/14/2019: AXGT, JNJ, BDX, PFE, ABT, MRK, AMGN.NEWS10: Health Care Sector Update for 03/14/2019: AXGT, JNJ, BDX, PFE, ABT, MRK, AMGN.NEWS11: Blue Chip Drug Stocks Face 'Reckoning' on Future Downgrades.

Answer: Rise